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ABSTRACT 
Polyserositis is defined as general inflammation of serous membranes associated with serous effusion due to many causes. 
In this study, we evaluated polyserositis as a rare complication of GCSF therapy. 
A 26-year-old man with a history of lymphoma was referred to our hospital complaining of dyspnea, tachycardia, tachypnea, 
chest pain, bilateral pleural effusion, ascites and massive pericardial effusion after 5 days of treatment with GCSF. 
After 7 days of treatment with indomethacin, dexamethasone and discontinuation of GCSF, the patient improved and was 
referred to an oncologist for chemotherapy of lymphoma. 
Based on this case report, we should consider various causes of pleural effusion in a patient with lymphoma, and use drugs 
with caution in such patients as they may be predisposed to dyspnea and fluid retention. (Tanaffos 2009; 8(3): 65-68) 
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INTRODUCTION 
Polyserositis is characterized by general 
inflammation of the serous membrane associated 
with serous effusion (1). 
Concato’s disease is defined as progressive 
malignant polyserositis with large effusions of 
pericardium, pleura and peritoneum (2). 
Granulocyte colony-stimulating factor (GCSF) is 
secreted by monocytes, endothelial cells, fibroblasts 
and neutrophils and induces the proliferation of  
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myeloid progenitor cells (2).Lymphoma is the third 
leading cause of malignant pleural effusion.  
The incidence of pleural effusion at presentation 
is 6% in cases with non-Hodgkin lymphoma and 
large cell lymphomas are more frequently associated 
with pleural diseases compared to small cell 
lymphoma. The cytology of the pleural fluid is 
positive almost in all cases (3).  
 
CASE SUMMARIES: 
Our patient was a 22-year-old male. He was a 
known case of mixed cellularity Hodgkin lymphoma 
(Figure1) diagnosed 10 months earlier and standard 
chemotherapy (ABVD regimen) treatment had been 
started for him. He had dyspnea, tachycardia, 
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tachypnea, chest pain and respiratory distress and 
therefore a pulmonary consultation was requested for 
him. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CT-Scan of the patient. 
 
He received 3 courses of chemotherapy and was 
improved after 4 months of treatment. However, he 
did not show up for the follow ups and after 5 
months  he presented  to an oncologist due to the 
recurrence of disease .At this time,  his only 
complaints were cough and mild dyspnea . 
Spiral CT-scan of the chest and mediastinum with 
contrast showed an anterior mediastinal mass without 
parenchymal or pleural involvement, cardiomegaly 
or ascites (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Spiral CT-Scan with contrast showed anterior         
mediastinal mass. 
The patient was admitted to the oncology ward 
and he was treated with GCSF before chemotherapy 
for prophylaxis of pancytopenia which had been 
occurred in the previous chemotherapy.  He did not 
receive any other medication. 
After 7 days of treatment with GCSF, symptoms 
of respiratory distress were developed and the case 
was consulted with a pulmonologist. On physical 
examination, he had tachypnea, tachycardia and 
respiratory distress. 
Initial examination showed an elevated jugular 
vein pressure (JVP) and decreased bilateral breath 
sounds at the lung bases associated with decreased 
heart sounds and ascites without peripheral edema. 
CXR showed bilateral pleural effusion and 
cardiomegaly with consolidation in the left upper 
lobe due to the mediastinal mass. 
Abdominal ultrasound showed ascites without 
hepatosplenomegaly or para-aortic lymphadenopathy 
(Figures 3). There was severe (massive) pericardial 
effusion (33mm) on echocardiography. 
Right ventricle was partially collapsed but left 
ventricle was normal. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Abdominal ultrasound showed ascites without 
hepatosplenomegaly 
 
Analysis of the pleural fluid showed the following 
results: WBC=6100 (with Neut=75%, Lymph=15%, 
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Eos=10%), RBC=290, glucose=73mg/dl, protein= 
1.3g/dl, LDH=937, and CEA=1.3 (normal=0-3). 
Pleural fluid cytology done at 2 steps was 
negative. 
Pleural biopsy showed no evidence of malignancy 
except acute inflammation.  
Blood analysis showed these findings: 
SGOT=60, SGPT=221, sodium=140, potassium=3.8, 
albumin =4.1, protein=5.9, Cr =0.9, BUN =20, 
LDH=864, and WBC=11000 with Poly=91%; 
Lymph=5%; Eos=4% 
HIV Ab, HCV Ab and HBS Ag were negative. 
Thyroid function tests were normal (T4=85.6; 
T3=105; TSH=0.68 ). 
Tumor markers were in normal range as well 
{CEA=0.5 (n 0-3.5), α-FP=2.3 (n=0-5), CA19-
9=9.7}. 
Since the cytology was normal, pleural biopsy 
was negative for malignancy and GCSF had been 
administered for 5 days, GCSF was discontinued and 
the patient was treated with dexamethasone and 
indomethacin due to the massive pericardial effusion 
and followed up by daily echocacardiography for 5 
days because of the risk of pericardial tamponade. 
After 5 days of treatment and withdrawal of 
GCSF, pericardial effusion improved (2 mm) and 
ascites and pleural effusion were resolved. After 1 
month the patient had no sign or symptom of 
polyserositis and was referred to the oncology ward 
for chemotherapy of lymphoma with ABVD but 
without GCSF. After 6 months of follow up, the 
patient has not shown any sign of polyserositis.  
 
DISCUSSION 
Our patient only received GCSF on the admission 
day and after 5-7 days he developed severe pleural 
and pericardial effusion, ascites, chest pain and 
respiratory distress. 
GCSF is a glycoprotein growth factor that 
promotes the proliferation of myeloid progenitor 
cells.  
The main adverse effects of GCSF during a short-
term treatment are musculoskeletal pain and dysuria. 
Hypersensitivity reactions have been rarely reported 
in patients receiving long-term treatments (5). 
The most frequent adverse effects are bone and 
musculoskeletal pain. Other side effects include 
splenic enlargement, thrombocytopenia, anemia, 
epistaxis, headache, diarrhea and cutaneous 
vasculitis. 
There have been reports on pulmonary infiltrates 
leading to respiratory failure, acute respiratory 
distress syndrome and anaphylactic reaction (7). 
Pleural and pericardial effusion and cardiac 
rhythm abnormality have been rarely reported (5). 
However, we could not find any case of polyserositis 
due to GCSF in the literature. 
There are several reports on exacerbation of 
chemotherapy-induced pulmonary toxicity in patients 
receiving GCSF in conjunction with bleomycin and 
cyclophosphamide (5,7);but our patient had received 
these drugs 5 months ago. 
In a series of 9 patients receiving prolonged 
treatment with GMCSF for myelodysplasia or 
aplastic anemia, 4 developed hypoalbuminemia that 
was symptomatic in 2 of them (5,8).But our patient 
did not receive GMCSF and did not develop 
hypoalbuminemia (albumin=4.1). 
GCSF should be used with caution in patients 
with fluid retention or heart failure as it may 
aggravate fluid retention and result in pulmonary 
edema and infiltration (5). Our patient however, had 
no sign or symptom of volume overload. 
Acute pleuropulmonary reaction is often 
accompanied by eosinophilia in both blood and 
pleural fluids (11) and our patient had eosinophilia 
(about 4%, 440) and the eosinophil count of his 
pleural fluid was 10%. 
Reactivation of various inflammatory disorders 
including RA and pseudogout has been reported 
following administration of GCSF (5, 9). However, 
www.SID.ir
Ar
ch
ive
 of 
SID
Rouhi Boroujeni H, et al   68 
Tanaffos 2009; 8(3): 65-68 
our patient had no evidence of collagen vascular 
disorders. 
Thus, as described above, polyserositis in our 
patient was due to treatment with GCSF and 
probably not due to lymphoma; and discontinuation 
of GCSF was the basic treatment for this patient. 
However, due to severe pericardial effusion and 
partial RV and RA collapse and risk of tamponade, 
treatment with dexamethasone and indomethacin was 
started. The patient responded well to these drugs 
and was referred for further chemotherapy. 
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